Press Releases

“We must not be fooled by a procedural vote. UsAgainstAlzheimer’s is concerned by any momentum in Congress to advance policies that may weaken or eliminate health care for people with Alzheimer’s and related dementias,” Vradenburg said. “We urge Congress to ensure that the impact of health reform on millions of elderly, sick and low-income Americans is a central consideration in any forthcoming deliberation of a replacement bill.” 

Twenty-seven Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer’s pipeline analysis presented today at the Alzheimer’s Association International Conference (AAIC) by ResearchersAgainstAlzheimer’s (RA2), an UsAgainstAlzheimer’s network. 

Following the release of the revised Better Care Reconciliation Act, UsAgainstAlzheimer’s maintains its opposition to any legislation that would reduce access to affordable care for millions of low-income, elderly and sick Americans, and may weaken protections for many Americans with or at risk of Alzheimer’s, a disease that has no cure and one that often goes misdiagnosed.  

UsAgainstAlzheimer’s applauds this bi-partisan acknowledgement of Alzheimer’s as a game-changing national public health threat and calls on the full House appropriations committee to finalize this investment in research for a disease that affects 5.5 million Americans and costs the nation more than $250 billion.

In response to the Congressional Budget Office (CBO) analysis that 22 million Americans would lose coverage by 2026 under the Senate plan, UsAgainstAlzheimer’s opposes any bill that would severely restrict access to essential medical and care services for individuals with dementia and their families.


^ Back to Top